The research on inhibitors of the CXCL12/HMGB1 heterocomplex was boosted by the results obtained in patients with RA and in vivo models of inflammation, in view of developing additional treatments for several pathological conditions fueled by monocyte infiltration (63–66). Here, CXCL12 is linked to rheumatoid arthritis.